You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

The Evolving Landscape for Advanced/Metastatic Urothelial Carcinoma: Where Might Emerging Targeted Therapies Fit?

  • Authors: Enrique Grande, MD, PhD; Andrea Necchi, MD; Daniel P. Petrylak, MD; Jens Bedke, MD
  • CPD Released: 1/12/2022
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 1/12/2023
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematologists, oncologists, urologists, and pathologists.

The goal of this activity is to improve physician awareness and understanding of the latest data with emerging targeted therapies for advanced/metastatic urothelial carcinoma reported at the 2021 European Society for Medical Oncology (ESMO) Congress, and their implications for ongoing/future management.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Latest clinical evidence with emerging targeted therapies for advanced/metastatic urothelial carcinoma
    • Clinical characteristics that may impact treatment decisions with emerging targeted therapies
  • Have greater competence related to
    • Selecting which patients with advanced/metastatic urothelial carcinoma could be suitable for treatment with emerging targeted therapies
  • Demonstrate greater confidence in their ability to
    • Understand the clinical implications of the latest trials data with emerging targeted therapies for the treatment paradigm of advanced advanced/metastatic urothelial carcinoma


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Enrique Grande, MD, PhD

    Director, Medical Oncology Program
    Clinical Research lead
    MD Anderson Cancer Center Madrid
    Madrid, Spain

    Disclosures

    Disclosure: Enrique Grande, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Eisai; Esteve; Lilly; Merck KGaA; Merck Sharpe & Dohme; Novartis; Pfizer; Roche
    Speaker or a member of a speakers bureau for: Adacap; Amgen; Angelini; Astellas; AstraZeneca; Bayer; Blueprint; Bristol Myers Squibb; Caris Life Sciences; Celgene; Clovis-Oncology; Eisai; Eusa Pharma; Genetracer; GlaxoSmithKline; Guardant Health; HRA-Pharma; Ipsen; ITM Radiopharma; Janssen; Lexicon; Lilly; Merck KGaA; Merck Sharpe & Dohme; Nanostring Technologies; Natera; Novartis; ONCODNA (Biosequence); Palex; Pharmamar; Pierre Fabre; Pfizer; Roche; Sanofi Genzyme; Servier; Taiho; Thermo Fisher Scientific
    Grants for clinical research from: Astellas; AstraZeneca; Ipsen; Lexicon; Merck KGaA; MTEM/Threshold; Nonostring Technologies; Pfizer; Roche

  • Andrea Necchi, MD

    Associate Professor
    Director of Genitourinary Medical Oncology
    Vita-Salute San Raffaele University
    IRCCS San Raffaele Hospital
    Milan, Italy

    Disclosures

    Disclosure: Andrea Necchi, MD, has the following relevant financial relationships:
    Advisor or consultant for: AstraZeneca; Bayer; Bristol Myers Squibb; Clovis Oncology; Incyte; Janssen; Merck; Rainer Therapeutics; Roche; Seattle Genetics/Astellas
    Grants for clinical research from: AstraZeneca; Foundation Medicine; Janssen; Merck; Roche

  • Daniel P. Petrylak, MD

    Professor of Medicine and Urology
    Smilow Cancer Hospital
    Yale University
    New Haven, Connecticut, United States

    Disclosures

    Disclosure: Daniel P. Petrylak, MD, has the following relevant financial relationships:
    Advisor or consultant for: Advanced Accelerator Applications; Amgen; Astellas; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol Myers Squibb; Clovis Oncology; Eli Lilly; Exelixis; Incyte; Ipsen; Janssen; Mirati; Monopteros; Pfizer; Pharmacyclis; Regeneron; Roche; Seattle Genetics; Urogen
    Grants for clinical research from: Advanced Accelerator Applications; Agensys Inc.; Astellas; AstraZeneca; Bayer; BioXcel Therapeutics; Bristol Myers Squibb; Clovis Oncology; Eisai; Eli Lilly; Endocyte; Genentech; Innocrin; MedImmune; Medication; Merck; Mirati; Novartis; Pfizer; Progenics; Replimmune; Roche; Sanofi; Aventis; Seattle Genetics
    Stocks, stock options, or bonds from: Bellicum; Tyme

  • Jens Bedke, MD

    Professor and Vice Chairman
    Department of Urology
    Eberhard Karls University Tübingen
    Tübingen, Germany

    Disclosures

    Disclosure: Jens Bedke, MD, has the following relevant financial relationships:
    Advisor or consultant for: Astellas; Bristol Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck; Merck Sharpe & Dohme; Nektar; Pfizer; Roche
    Speaker or a member of a speakers bureau for: AstraZeneca; Astellas; Bristol Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck; Merck Sharpe & Dohme; Novartis; Pfizer; Roche
    Grants for clinical research from: Eisai; Ipsen; Merck Sharpe & Dohme; Novartis; Roche; Pfizer; Seagen

Editors

  • Megan Cannon, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Megan Cannon, PhD, has disclosed no relevant financial relationships.

  • Chii Shyang Fong, PhD

    Chii Shyang Fong, PhD
    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Disclosure: Chii Shyang Fong, PhD, has disclosed no relevant financial relationships.

Content Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.5 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

The Evolving Landscape for Advanced/Metastatic Urothelial Carcinoma: Where Might Emerging Targeted Therapies Fit?

Authors: Enrique Grande, MD, PhD; Andrea Necchi, MD; Daniel P. Petrylak, MD; Jens Bedke, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 1/12/2022

Valid for credit through: 1/12/2023

processing....

Educational Impact Challenge

The goal of this activity is to improve physician awareness and understanding of the latest data with emerging targeted therapies for advanced/metastatic urothelial carcinoma reported at the 2021 European Society for Medical Oncology (ESMO) Congress, and their implications for ongoing/future management.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print